BIIB - Longeveron: Speculative Biotech Worth A Look On Rare Disease Aging And Alzheimer's Focuses
- Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome.
- All 10 patients who received Lomecel-B were alive and had not required a transplant between 2 to 3.5 years post-surgery.
- Longeveron had initiated a phase 2a study using Lomecel-B for the treatment of patients with mild AD; a phase 1 study showed a slower cognitive decline in Lomecel-B treated patients.
- The global market opportunity for Alzheimer's disease could reach $17.7 billion by 2025.
For further details see:
Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses